Regulatory Affairs 30 March 2026

News·Nuclear Energy·Regulatory Affairs·Stock Market

Oklo Stock Just Got an NRC Win. The Real Test Comes May 12

Oklo shares fell 3.6% to $76.76 Thursday, retracing gains after the U.S. Nuclear Regulatory Commission approved its Aurora powerhouse design criteria. The company will report first-quarter results after market close May 12, with analysts expecting a loss of 20 cents per share. Oklo ended 2025 with $1.41 billion in cash and a $105.7 million net loss.

May 7, 2026

Health·News·Pharmaceuticals·Regulatory Affairs

GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review

China approved GSK’s asthma drug Exdensur for patients 12 and older and accepted its hepatitis B candidate bepirovirsen for regulatory review, the company said Monday. Exdensur’s approval followed trials showing it reduced annual asthma attacks by up to 58% versus placebo. The drug will compete with Dupixent and Xolair. Bepirovirsen targets chronic hepatitis B, where current treatments rarely clear the virus.

March 30, 2026

Automotive·Finance·News·Regulatory Affairs

Lloyds Faces Fresh Car Finance Pressure as FCA Opens Taskforce Ahead of Payout Ruling

UK regulators launched a taskforce Monday to target motor finance claims firms as Lloyds Banking Group faces a £66 million lawsuit from over 30,000 borrowers alleging mis-sold car loans. The Financial Conduct Authority is set to announce final compensation rules later today. Lloyds has set aside £1.95 billion for the scandal, but actual costs may change. Other banks, including Santander and Barclays, are also exposed.

March 30, 2026